Primary prevention of sudden cardiac death

Heart

Volumn 92, Issue 12, 2006, Pages 1873-1878

  Kirchhof, Paulus ^a,b   Breithardt, Günter ^a   Eckardt, Lars ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b Interdisciplinary Center of Clinical Research IZKF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BRUGADA SYNDROME; CLINICAL FEATURE; CONGENITAL DISORDER; CORONARY ARTERY DISEASE; DIAGNOSTIC PROCEDURE; DISEASE COURSE; ELECTROCARDIOGRAPHY; FABRY DISEASE; FAMILIAL HYPERTROPHIC CARDIOMYOPATHY; GENETIC DISORDER; HEART ARRHYTHMIA; HEART ELECTROPHYSIOLOGY; HEART RIGHT VENTRICLE DYSPLASIA; HEART VENTRICLE TACHYCARDIA; HUMAN; LONG QT SYNDROME; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; RISK FACTOR; SUDDEN DEATH; TORSADE DES POINTES; VALVULAR HEART DISEASE; WOLFF PARKINSON WHITE SYNDROME;

ARRHYTHMIA; CARDIOMYOPATHIES; CORONARY ARTERIOSCLEROSIS; DEATH, SUDDEN, CARDIAC; ECHOCARDIOGRAPHY; GENETIC SCREENING; HUMANS; RISK ASSESSMENT;

EID: 33845198651     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2006.087957     Document Type: Review

References (19)

1. Priori SG, Aliot E, Blomstrom-Lundqvist C, et al. Update of the guidelines on sudden cardiac death of the European Society of Cardiology. Eur Heart J 2003;24:13-15. ▶ The article provides the current recommendations of the European Society of Cardiology.
2. Huikuri HV, Castellanos A, Myerburg RJ. Sudden death due to cardiac arrhythmias. N Engl J Med 2001;345:1473-82. ▶ A recent overview on the incidence and putative aetiology of SCD. This knowledge is required for the understanding of the interventions to prevent SCD.
3. Desai AS, Fang JC, Maisel WH, et al. Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy: a meta-analysis of randomized controlled trials. JAMA 2004;292:2874-9.
4. Nanthakumar K, Epstein AE, Kay GN, et al. Prophylactic implantable cardioverter-defibrillator therapy in patients with left ventricular systolic dysfunction: a pooled analysis of 10 primary prevention trials. J Am Coll Cardiol 2004;44:2166-72. ▶ A relevant meta-analysis of defibrillator trials - a good start for reading through this extensive body of published large controlled trials.
5. Wang C, Chung M, Lichtenstein A, et al. Effects of omega-3 fatty acids on cardiovascular disease. Evid Rep Technol Assess (Summ) 2004:1-8.
6. Julian DG, Camm AJ, Frangin G, et al. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators. Lancet 1997;349:667-74.
7. Singh SN, Fletcher RD, Fisher SG, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N Engl J Med 1995;333:77-82.
8. Priori SG, Schwartz PJ, Napolitano C, et al. Risk stratification in the long-QT syndrome. N Engl J Med 2003;348:1866-74. ▶ A large observational study that gives a good indication of how dangerous long QT syndrome can be.
9. Gaita F, Giustetto C, Bianchi F, et al. Short QT syndrome: a familial cause of sudden death. Circulation 2003;108:965-70.
10. Antz M, Weiss C, Volkmer M, et al. Risk of sudden death after successful accessory atrioventricular pathway ablation in resuscitated patients with Wolff-Parkinson-White syndrome. J Cardiovasc Electrophysiol 2002;13:231-6.
11. Antzelevitch C, Brugada P, Borggrefe M, et al. Brugada syndrome: report of the second consensus conference: endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. Circulation 2005;111:659-70.
12. Elliott P, McKenna WJ. Hypertrophic cardiomyopathy. Lancet 2004;363:1881-91. ▶ A good introduction to this common inherited arrhythmogenic disease.
13. Wichter T, Paul TM, Eckardt L, et al. Arrhythmogenic right ventricular cardiomyopathy: antiarrhythmic drugs, catheter ablation, or ICD? Herz 2005;30:91-101. ▶ A nice overview of this probably under-diagnosed arrhythmogenic disease. There is probably more to come in this field in the near future.
14. Haverkamp W, Breithardt G, Camm J, et al. The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology. Cardiovasc Res 2000;47:219-33. ▶ A comprehensive overview of current understanding of pro-arrhythmia.
15. Ray WA, Murray KT, Meredith S, et al. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med 2004;351:1089-96. ▶ Sudden cardiac death can be caused by non-cardiac drugs!
16. MERIT-HP Investigators. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001-7.
17. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-17.
18. Domanski MJ, Exner DV, Borkowf CB, et al. Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction. A meta-analysis of randomized clinical trials. J Am Coll Cardiol 1999;33:598-604. ▶ A nice review of the effect of ACE inhibition for sudden death prevention.
19. Awtry EH, Loscalzo J. Aspirin. Circulation 2000;101:1206-18.